NCT00637221View on ClinicalTrials.gov

Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and Continuous Performance Tasks, Adults With Fragile X Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Fragile X Syndrome
Interventions
DRUG

NPL-2009

Single doses of either 50mg, 100 mg or 150 mg NPL-2009

Trial Locations (2)

60612

Rush University Medical Centre, Chicago

95817

MIND Institute, Sacramento

Sponsors

Lead Sponsor

Neuropharm
All Listed Sponsors
lead

Neuropharm

INDUSTRY